New Challenge to Thai Drug Licensing (Thailand)
This article was originally published in PharmAsia News
Executive Summary
Emcure Pharmaceuticals is being threatened with legal action by the Sanofi-Aventis, patent holder of the cardiac drug Plavix. Emcure secured an order from the Thai government to produce clopidogrel, the generic version of Plavix. In a notice to Bioscience Co. Ltd, the agent of Emcure in Thailand, Sanofi-Aventis said that any unauthorized importation, manufacture, and sale of the generic clopidogrel will infringe Sanofi's patent rights of clopidogrel under Thai law. Sanofi says that in the event of infringement of its patent, the company "will be entitled to sue the company in a civil action for compensation. Emcure says it has received assurances of support from the Thai government. (Click here for more
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.